Tags : SNK01


Merck KGaA Expand its Collaboration with NKMax to Evaluate the

Shots: The companies plan to conduct a P-I/IIa trial assessing the safety and anti-tumor activity of SNK01 + gemcitabine/carboplatin or gemcitabine/carboplatin + Erbitux (cetuximab) in patients with LA or mNSCLC after prior TKI therapy NKMax will sponsor the study while Merck KGaA will supply cetuximab (250 mg/m2, wq, IV) for P- I/IIa trial in NSCLC […]Read More